LaSalle St. Investment Advisors LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 829 shares of the medical research company’s stock, valued at approximately $416,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC grew its stake in Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after buying an additional 20 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its holdings in Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares in the last quarter. Confluence Wealth Services Inc. boosted its stake in Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock worth $2,487,000 after purchasing an additional 22 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Thermo Fisher Scientific by 0.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company’s stock valued at $2,311,000 after buying an additional 22 shares in the last quarter. 89.23% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,493 shares of company stock worth $37,657,681 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Stock Up 2.4%
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.
Analyst Ratings Changes
A number of brokerages have commented on TMO. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $619.41.
Get Our Latest Research Report on TMO
Thermo Fisher Scientific Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
